SMSbiotech, Inc
SMSbiotech is a clinical-stage regenerative medicine company developing a proprietary Small Mobile Stem (SMS) cell therapy platform derived from adult human blood, with a lead Phase 1b program in COPD and pipeline expansion into orthopedics, veterinary, and cosmeceutical indications.
- Company typePrivate
- Founded2015
- HeadquartersSan Marcos, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What SMSbiotech, Inc does
SMSbiotech, Inc. is a clinical-stage regenerative medicine company founded in 2015 and headquartered in San Marcos, California. It has developed a proprietary Small Mobile Stem (SMS) cell therapy platform based on a novel population of adult stem cells derived from human peripheral blood, protected by 15 filed patents (7 granted) in the U.S., Europe, and Japan. The lead therapeutic program targets Chronic Obstructive Pulmonary Disease (COPD) and is currently in a Phase 1b clinical trial conducted in Australia under TGA and HREC approvals, with first patients dosed in mid-2025 and no adverse events reported to date; management plans to advance the program into U.S. clinical development and Phase 2.
The broader pipeline extends to lung fibrosis, orthopedic conditions (knee osteoarthritis, degenerative disc disease), veterinary applications for dogs and horses, and cosmeceutical skin treatments, plus a bioproduction catalog of cell culture media, sera, reagents, single-use fluid containment systems, and bioreactors/mixers sold to research and bioprocessing customers. Manufacturing infrastructure includes ISO-7 certified clean rooms in Carlsbad, California, and a cGMP facility under development with planned completion in Q1 2026. A research product, ANGIOstream™ In Vitro Assay, supports microvessel formation studies.
The company is pre-revenue, privately held, and accessible only to accredited investors. Management's stated revenue strategy relies on (1) compassionate use / expanded access programs internationally and in the U.S. during Phase 1, (2) animal health and licensing/partnership deals, and (3) future commercial sales of approved COPD and other indication therapies. Management projects that capturing 2.5% of the U.S. COPD market would generate $500 million in sales and $350 million in EBITDA at maturity. The company has been reinforced by the recent appointments of Joe Kiani (founder of Masimo) as Chairman and Michael C. Swartzburg, formerly of Iovance Biotherapeutics and Dermavant Sciences, as Chief Financial Officer, signaling preparation for clinical scaling and a potential future capital markets event.
SMSbiotech, Inc firmographics
Firmographics- Name
- SMSbiotech, Inc
- Legal name
- SMSbiotech, Inc.
- Website
- https://smsbiotech.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SMSbiotech is a clinical-stage regenerative medicine company developing a proprietary Small Mobile Stem (SMS) cell therapy platform derived from adult human blood, with a lead Phase 1b program in COPD and pipeline expansion into orthopedics, veterinary, and cosmeceutical indications.
- Ownership category
- akta.pro rank
SMSbiotech, Inc industry classification
Industry- Product category
- Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
- akta.pro secondary industries
- Cell Therapy CDMO (HLAGABAD), Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where SMSbiotech, Inc is headquartered
LocationHeadquarters
- HQ city
- San Marcos
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
SMSbiotech, Inc business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Compassionate Use / Expanded Access Programs: SMSbiotech plans to apply for compassionate use worldwide to generate early revenues prior to full commercial approval. The company has obtained approval from a U.S. IRB for expanded access applications in COPD. Revenue expected to begin during Phase I COPD clinical trial through compassionate use treatments globally.
- Animal Health Products: SMS cell therapy being developed for veterinary applications including dogs and horses. Company is pursuing animal health indications especially those relevant to human diseases.
- Licensing and Partnerships: Platform technology targeting multiple indications creates opportunities for licensing, royalty deals, and partnerships with major industry players. Company plans multiple exits through licensing, partnerships, and acquisitions.
- Future Commercial Products: Upon FDA approval and commercialization of COPD and other indications, expected to generate significant revenue through direct sales and partnerships. Company projects acquiring 2.5% US COPD market share would generate $500 million in sales and $350 million in EBITDA.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
SMSbiotech, Inc product offering
Product offeringCore offering
SMSbiotech is a clinical-stage regenerative medicine company developing a proprietary Small Mobile Stem (SMS) cell therapy platform derived from adult human blood. The allogeneic, off-the-shelf platform produces cells for multiple indications, with the lead program targeting Chronic Obstructive Pulmonary Disease (COPD) via nebulizer inhalation, currently in Phase 1b clinical trials in Australia. The company also manufactures and sells bioproduction consumables (cell culture media, sera, reagents, single-use fluid containment systems, bioprocessing equipment) directly to bioprocessing companies.
Product overview
SMSbiotech is a clinical-stage regenerative medicine company that has developed a proprietary Small Mobile Stem (SMS) cell therapy platform as its core technology. The platform produces allogeneic, off-the-shelf stem cell therapies derived from adult human blood that can be administered via inhalation or injection. The lead product is an SMS cell therapy for COPD currently in Phase 1b clinical trials. The company operates two distinct business lines: (1) therapeutic programs including SMS cell therapies for COPD, lung fibrosis, orthopedic conditions (joint therapy, disc degeneration), veterinary applications (dogs and horses), and cosmeceutical skin treatments; and (2) biomanufacturing products including cell culture media, sera, reagents, buffers, single-use fluid containment systems, and bioproduction instruments/equipment for the bioprocessing industry. The company also offers the ANGIOstream™ In Vitro Assay research product and compassionate use programs for early patient access.
Differentiator
Problem solved
Functional benefit
Products and services
- Small Mobile Stem (SMS) Cell Therapy Platform Allogeneic, off-the-shelf stem cell therapy platform derived from adult human blood, designed to enable systemic, scalable, repeatable regenerative treatments for chronic and degenerative diseases. Can be administered via inhalation or injection.
- SMS Cell Therapy for COPD Lead therapeutic program targeting Chronic Obstructive Pulmonary Disease (COPD), currently in Phase 1b clinical trials. The therapy aims to regenerate damaged alveolar lung tissue through inhalation administration of SMS cells via nebulizer.
- SMS Cell Therapy for Lung Fibrosis Cell therapy program targeting lung fibrosis as part of the respiratory care pipeline, currently in Phase I clinical trials.
- SMS Cell Therapy for Orthopedic Conditions Cell therapy in development for chronic orthopedic conditions in humans, including joint therapy and disc degeneration, with programs ranging from pre-clinical to clinical submission stages.
- SMS Cell Therapy for Veterinary Applications Cell therapy products being developed for animal health applications, particularly dogs and horses, for conditions such as joint therapy and wound healing.
- SMS Cell Cosmeceutical Products Cosmeceutical applications of SMS cell technology for skin anti-aging and scar treatment, currently in research and development stages, with evidence of faster recovery after RF microneedling.
- Cell Culture Media Consumable SMSbiotech products used in bioproduction processes, including cell culture media for cell therapy manufacturing. Sold to bioprocessing and biomanufacturing companies for research use or further manufacturing.
- Sera and Reagents Consumable biological products including sera, reagents, buffers, process liquids, chemicals, compounds, and supplements for bioproduction processes. Sold to bioprocessing and biomanufacturing companies for research use or further manufacturing.
- Single-Use Fluid Containment Systems Single-use flexible and rigid fluid containment systems for bioprocessing and liquid handling, including system components such as containers, bags, liners, ports, tubing, fittings, manifolds, filters, sensors, and end treatments.
- Bioproduction Instruments and Equipment Durable bioproduction and bioprocess liquid handling instruments and equipment including bins, vessels, single-use bioreactors, single-use mixers, and single-use fermenters.
- ANGIOstream In Vitro Assay In vitro assay product with Fast Track Option - Inductive Niche Module (INM) designed to fast-track stable microvessel formation from primary endothelial cells using human stem cells.
- Compassionate Use Program Early access / compassionate use pathway for SMS cell therapy, enabling revenue generation prior to full commercial approval. Company obtained US IRB approval for expanded access applications in COPD.
Quantifiable outcome
- Global COPD market: $19.8 billion (2021), growing at 5% CAGR. US COPD burden: $50 billion annually.
- +3 more outcomes
Companies that use SMSbiotech, Inc
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
SMSbiotech, Inc technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
SMSbiotech, Inc partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Veritus ResearchcoreVeritus Research is conducting SMSbiotech's Phase I clinical trial for COPD in Australia under Australian TGA and HREC approvals. Trial enrolled 18 COPD patients to evaluate safety and tolerability of SMS cell therapy.
- U.S. Army Medical Research Institute of Chemical Defense (USAMRICD)coreCollaborative Research and Development Agreement (CRADA) established for military-led animal study collaboration. Represents strategic relationship with U.S. military for research applications of SMS cell technology.
- BiocomminorParticipation in Biocom Regenerative Medicine Fly-In to Washington DC meeting with NIH, FDA, and U.S. Representatives to advocate for regenerative medicine field and patient care priorities.
- Knobbe MartenscoreOne of the nation's leading intellectual property law firms managing SMSbiotech's global patent portfolio. Filed 15 patents worldwide with 7 granted as of September 2025.
- Acculab Life SciencesminorCollaboration announced for advancement of cell therapy research and development initiatives.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
SMSbiotech, Inc competitors and assessment
Company assessmentDirect peers
- Mesoblast: Mesoblast develops allogeneic, off-the-shelf cell therapies (remestemcel-L, rexlemestrocel) including programs targeting inflammatory and chronic pulmonary diseases such as COPD and ARDS. Most directly comparable to SMSbiotech as an allogeneic cell therapy developer pursuing respiratory indications.
- Athersys / Healios K.K. Healios (partner of Athersys) develops MultiStem, an allogeneic, off-the-shelf cell therapy platform with clinical programs in acute respiratory distress syndrome (ARDS) and other inflammatory indications. Directly comparable allogeneic platform targeting respiratory disease.
- Pluristem Therapeutics: Pluristem develops placenta-derived, off-the-shelf allogeneic cell therapy products (PLX cells) targeting inflammatory and ischemic conditions. Comparable as an allogeneic cell therapy developer pursuing regenerative indications.
- BrainStorm Cell Therapeutics: BrainStorm develops autologous MSC-NTF cell therapy (NurOwn) for neurodegenerative diseases. Comparable as a clinical-stage cell therapy developer with regulatory engagement and similar manufacturing/clinical scaling challenges.
- Celularity Inc. Celularity develops allogeneic, off-the-shelf cell therapies derived from the placenta, targeting cancer, autoimmune, and degenerative diseases. Comparable as an allogeneic cell therapy platform with multi-indication pipeline approach.
- Cynata Therapeutics: Cynata develops allogeneic induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell therapies using its Cymerus platform. Comparable as an allogeneic cell therapy developer with platform approach targeting multiple inflammatory indications.
Emerging players
- Capstan Therapeutics: Capstan is an emerging cell therapy company developing in vivo cell engineering approaches using lipid nanoparticles to deliver mRNA to immune cells. Comparable as a next-generation cell therapy platform targeting inflammatory and regenerative indications.
- PharmaCyte Biotech: PharmaCyte develops cell encapsulation-based therapies for cancer and chronic diseases, including diabetes. Comparable as a clinical-stage cell therapy developer pursuing encapsulation/delivery innovation for chronic conditions.
Broad incumbents
- BlueRock Therapeutics: BlueRock Therapeutics (Bayer subsidiary) develops engineered cell therapies including iPSC-derived dopaminergic neurons and cardiac cell therapies. Comparable as a well-capitalized cell therapy platform pursuing regenerative medicine, though focused on different indications.
- Vertex Pharmaceuticals (Cell Therapy Division): Vertex acquired ViaCyte and Semma Therapeutics to build a cell therapy franchise targeting type 1 diabetes and other chronic diseases. Comparable as a major biopharma with substantial cell therapy capabilities pursuing disease-modifying regenerative approaches.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
SMSbiotech, Inc social profiles
Digital presenceSMSbiotech, Inc compliance and trust
Trust signalCompliance3 records
SMSbiotech, Inc financial estimates
Financial estimateRevenue estimate
Valuation estimate
SMSbiotech, Inc leadership team
Management profileNumber of profiles
Profiles6 records
SMSbiotech, Inc funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SMSbiotech, Inc M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SMSbiotech, Inc
What does SMSbiotech, Inc do?
SMSbiotech is a clinical-stage regenerative medicine company developing a proprietary Small Mobile Stem (SMS) cell therapy platform derived from adult human blood. The allogeneic, off-the-shelf platform produces cells for multiple indications, with the lead program targeting Chronic Obstructive Pulmonary Disease (COPD) via nebulizer inhalation, currently in Phase 1b clinical trials in Australia. The company also manufactures and sells bioproduction consumables (cell culture media, sera, reagents, single-use fluid containment systems, bioprocessing equipment) directly to bioprocessing companies.
Is SMSbiotech, Inc a public or private company?
SMSbiotech, Inc is a private company. It is classified as venture growth investor backed and is currently operating.
When was SMSbiotech, Inc founded?
SMSbiotech, Inc was founded in 2015. It employs 11 to 50 people.
Where is SMSbiotech, Inc based?
SMSbiotech, Inc is headquartered in San Marcos, United States, in the North America region.
How does SMSbiotech, Inc make money?
Four revenue lines are on record. Compassionate Use / Expanded Access Programs are the primary driver. The others are animal Health Products, licensing and Partnerships and future Commercial Products.
Who are SMSbiotech, Inc's main competitors?
Direct peers on record are Mesoblast, Athersys / Healios K.K., Pluristem Therapeutics, BrainStorm Cell Therapeutics, Celularity Inc. and Cynata Therapeutics. Emerging players are Capstan Therapeutics and PharmaCyte Biotech. Broad incumbents are BlueRock Therapeutics and Vertex Pharmaceuticals (Cell Therapy Division).
Does SMSbiotech, Inc have an API?
No public API is recorded for SMSbiotech, Inc.
What industry is SMSbiotech, Inc in?
SMSbiotech, Inc's product category is Cell Therapy. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 325414 and its SIC code is 2836.